We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Topical cosmetic ingredient — not a dietary supplement
Tranexamic Acid (topical) is a topical cosmetic ingredient, not a supplement you take internally and not a drug. It is sold legally in skincare products to affect the appearance of skin (such as wrinkles). The evidence below comes mostly from small, often industry-funded studies of topical application, so treat the effect sizes cautiously. This page is for transparency and education, not a recommendation.
What the evidence says
Most Tranexamic Acid (topical) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2014–2026 with a typical study size of 44 participants.
Based on 6 studies · 2 meta-analyses · 3 RCTs · 114 total participants
Confidence
HighBy outcome
Tranexamic Acid (topical) has an evidence score of 6/10 — moderate evidence based on 6 indexed studies, including 2 meta-analyses. A topical brightening active applied to the skin for melasma and stubborn pigmentation — a cosmetic/derm active, not (in this context) ingested. Tranexamic acid (a drug best known as an antifibrinolytic) interrupts the plasmin signalling that activates melanocytes, reducing pigment. The honest framing: topical TXA performs comparably to hydroquinone in small split-face trials and is very well tolerated, but the strongest melasma evidence — a placebo-controlled RCT and favorable meta-analysis rankings — is for ORAL tranexamic acid, not topical, and topical efficacy is limited by skin penetration. A network meta-analysis ranks topical TXA below oral TXA, lasers, and triple-combination cream. These are cosmetic appearance outcomes, not health outcomes. Representative study: PMID 34660626.
Practical, evidence-based guides that cover Tranexamic Acid (topical).
Explore: Best supplements for Skin, Hair & Beauty
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tranexamic Acid (topical, for melasma)
A topical brightening active applied to the skin for melasma and stubborn pigmentation — a cosmetic/derm active, not (in this context) ingested. Tranexamic acid (a drug best known as an antifibrinolytic) interrupts the plasmin signalling that activates melanocytes, reducing pigment. The honest framing: topical TXA performs comparably to hydroquinone in small split-face trials and is very well tolerated, but the strongest melasma evidence — a placebo-controlled RCT and favorable meta-analysis rankings — is for ORAL tranexamic acid, not topical, and topical efficacy is limited by skin penetration. A network meta-analysis ranks topical TXA below oral TXA, lasers, and triple-combination cream. These are cosmetic appearance outcomes, not health outcomes.
A coherent plasmin-inhibition mechanism and multiple small split-face RCTs show topical TXA performs comparably to hydroquinone for melasma with excellent tolerability — but the strongest, placebo-controlled evidence is for ORAL TXA, network meta-analysis ranks topical TXA below oral/laser/triple-combination options, and topical penetration is a limit.
Tranexamic acid (TXA) is a synthetic lysine analogue best known as an antifibrinolytic medication; in dermatology it is used — orally, by injection, and topically — to treat melasma and stubborn hyperpigmentation.
This entry covers TOPICAL cosmetic/derm use (typically ~2-5% in serums); it is not about the ingested medication.
Mechanistically, TXA inhibits the plasminogen/plasmin pathway: by reducing plasmin in keratinocytes it dampens the UV-triggered signalling (arachidonic acid, prostaglandins, and melanocyte-stimulating factors) that activates melanocytes, and it can directly reduce melanin synthesis in melanoma cells, with an additive effect alongside arbutin in vitro.
The clinical evidence for topical TXA is genuine but modest and dominated by small split-face trials.
A double-blind split-face RCT (Ebrahimi & Naeini, 2014; 50 patients) found 3% topical TXA reduced MASI comparably to a 3% hydroquinone + 0.01% dexamethasone gold-standard, with significantly fewer side effects; a more recent split-face RCT in skin of color (Yasnova et al., 2024; 20 patients) similarly found 3% TXA cream as effective and safe as 4% hydroquinone.
The honest counterweights are decisive on where the strongest evidence sits: a route-comparison meta-analysis (Calacattawi et al., 2024; 22 RCTs, 1280 patients) found oral TXA produced the largest MASI reduction, ahead of injection and topical; and a network meta-analysis (Liu et al., 2021; 59 RCTs) ranked topical TXA below oral TXA, several lasers, triple-combination cream, and topical vitamin C, while also flagging a relatively high topical side-effect rate (~37%).
Topical penetration of this hydrophilic molecule is the recognised limit.
So the honest summary: topical TXA is a legitimate, well-tolerated, roughly hydroquinone-equivalent option for melasma in small trials, but it is not first-line and the oral route has better-quality support (oral TXA is a prescription use with its own clotting-risk considerations, separate from this topical entry).
None of this is a health claim. It is listed under Beauty & Appearance so it is discoverable, but is sandboxed out of ingestible-supplement stacks and the schedule optimizer; it carries a cosmetic badge and a topical-only disclaimer.
Tranexamic acid inhibits the plasminogen/plasmin system. In skin, less plasmin in keratinocytes means less UV-triggered release of the arachidonic-acid/prostaglandin and melanocyte-stimulating signals that drive pigment production — reducing melanocyte activation. It can also directly lower melanin synthesis in melanoma cells.
Melasma involves increased dermal vessels; TXA's antifibrinolytic/anti-angiogenic actions are proposed to reduce the vascular component of melasma, complementing its direct effect on pigment.
Topical use, typically ~2-5% tranexamic acid in a serum applied to areas of melasma once or twice daily, alongside daily sunscreen. There is no oral or systemic dose in this cosmetic context — the ingested medication is a separate prescription use with clotting-risk considerations. This library does not provide an ingestion protocol.
| Form | Type |
|---|---|
| 🧴Leave-on topical serum (≈2-5% tranexamic acid) | Recommended |
| 💊Combination brightening serums containing tranexamic acid | Alternative |
There is no cosmetic oral form here; oral tranexamic acid is a separate prescription use with clotting-risk considerations.
Minimum: 8 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Applied to melasma areas once or twice daily. As a leave-on topical there is no ingestion or meal-timing consideration; daily sunscreen is essential.
The documented benefit is a reduction in the APPEARANCE of melasma/pigmentation. Topical tranexamic acid is used here as a skincare active, not an ingested medication, and it does not treat any disease.
Small split-face trials show topical TXA reduces melasma comparably to hydroquinone. It is a useful option, especially for those who don't tolerate hydroquinone.
Topical TXA had the lowest irritation rate among topical depigmenting agents in a meta-analysis and caused fewer side effects than hydroquinone in head-to-head trials.
The best melasma evidence for tranexamic acid is for the ORAL route (placebo-controlled RCT; top route in meta-analysis). Topical is a gentler but weaker option, limited by skin penetration. Oral TXA is a prescription decision with clotting-risk considerations.
Topical use has limited data; discuss with a clinician. Do not take oral tranexamic acid for melasma in pregnancy without medical guidance.
This caution applies to ORAL/systemic tranexamic acid, not topical; never self-source oral TXA — it is a clinician decision.
Topical TXA is a gentle option; oral TXA, lasers, or triple-combination cream have stronger evidence — discuss with a dermatologist. Daily sunscreen is essential.
Generally layers well with niacinamide, vitamin C, and others; combining many actives can still irritate sensitive skin. This is a tolerability/formulation note, not a systemic drug interaction — topical use is not ingested. (Note: ORAL tranexamic acid does have systemic interactions/clotting considerations and is a separate prescription decision.)
Tip: Reduce frequency or concentration; patch-test on sensitive skin.
The commonly studied dose of Tranexamic Acid (topical) is Topical use, typically ~2-5% tranexamic acid in a serum applied to areas of melasma once or twice daily, alongside daily sunscreen. There is no oral or systemic dose in this cosmetic context — the ingested medication is a separate prescription use with clotting-risk considerations. This library does not provide an ingestion protocol.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Tranexamic Acid (topical) — consistent daily use matters more than the time of day. Topical tranexamic acid is a leave-on serum with no meal-timing relationship; consistent use plus daily sunscreen matters most for melasma.
Tranexamic Acid (topical) is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are mild local irritation or redness. Use caution if any of these apply to you: Topical use here is for skin only — do not self-medicate with oral tranexamic acid for melasma without a clinician (clotting-risk considerations); Known allergy or sensitivity to tranexamic acid or formulation excipients; Application to broken, irritated, or compromised skin until healed.